Cargando…

Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study

BACKGROUND: DSM265 is a novel antimalarial that inhibits plasmodial dihydroorotate dehydrogenase, an enzyme essential for pyrimidine biosynthesis. We investigated the safety, tolerability, and pharmacokinetics of DSM265, and tested its antimalarial activity. METHODS: Healthy participants aged 18–55...

Descripción completa

Detalles Bibliográficos
Autores principales:	McCarthy, James S, Lotharius, Julie, Rückle, Thomas, Chalon, Stephan, Phillips, Margaret A, Elliott, Suzanne, Sekuloski, Silvana, Griffin, Paul, Ng, Caroline L, Fidock, David A, Marquart, Louise, Williams, Noelle S, Gobeau, Nathalie, Bebrevska, Lidiya, Rosario, Maria, Marsh, Kennan, Möhrle, Jörg J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Science ;, The Lancet Pub. Group 2017
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5446412/ https://www.ncbi.nlm.nih.gov/pubmed/28363636 http://dx.doi.org/10.1016/S1473-3099(17)30171-8

Ejemplares similares

A Single-Dose Combination Study with the Experimental Antimalarials Artefenomel and DSM265 To Determine Safety and Antimalarial Activity against Blood-Stage Plasmodium falciparum in Healthy Volunteers
por: McCarthy, James S., et al.
Publicado: (2019)

DSM265 at 400 Milligrams Clears Asexual Stage Parasites but Not Mature Gametocytes from the Blood of Healthy Subjects Experimentally Infected with Plasmodium falciparum
por: Collins, Katharine A., et al.
Publicado: (2019)

Antimalarial Activity of Artefenomel Against Asexual Parasites and Transmissible Gametocytes During Experimental Blood-Stage Plasmodium vivax Infection
por: Collins, Katharine A, et al.
Publicado: (2020)

A Phase 1, Placebo-controlled, Randomized, Single Ascending Dose Study and a Volunteer Infection Study to Characterize the Safety, Pharmacokinetics, and Antimalarial Activity of the Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048
por: McCarthy, James S, et al.
Publicado: (2020)

DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection
por: Sulyok, Mihály, et al.
Publicado: (2017)

Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study
por: Llanos-Cuentas, Alejandro, et al.
Publicado: (2018)

A Pilot Randomised Trial of Induced Blood-Stage Plasmodium falciparum Infections in Healthy Volunteers for Testing Efficacy of New Antimalarial Drugs
por: McCarthy, James S., et al.
Publicado: (2011)

Parasite-Host Dynamics throughout Antimalarial Drug Development Stages Complicate the Translation of Parasite Clearance
por: Burgert, Lydia, et al.
Publicado: (2021)

Population Pharmacokinetics and Pharmacodynamics of Chloroquine in a Plasmodium vivax Volunteer Infection Study
por: Abd‐Rahman, Azrin N., et al.
Publicado: (2020)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Linking Murine and Human Plasmodium falciparum Challenge Models in a Translational Path for Antimalarial Drug Development
por: McCarthy, James S., et al.
Publicado: (2016)

Retrospective Analysis Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation Offers Improvements in Efficiency of the Design of Volunteer Infection Studies for Antimalarial Drug Development
por: Andrews, Kayla Ann, et al.
Publicado: (2020)

Piperaquine Monotherapy of Drug-Susceptible Plasmodium falciparum Infection Results in Rapid Clearance of Parasitemia but Is Followed by the Appearance of Gametocytemia
por: Pasay, Cielo J., et al.
Publicado: (2016)

Ensemble modeling highlights importance of understanding parasite-host behavior in preclinical antimalarial drug development
por: Burgert, Lydia, et al.
Publicado: (2020)

Parasite Viability as a Measure of In Vivo Drug Activity in Preclinical and Early Clinical Antimalarial Drug Assessment
por: Radohery, Georges F. R., et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers
por: Sinxadi, Phumla, et al.
Publicado: (2020)

A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study
por: McCarthy, James S., et al.
Publicado: (2016)

Combining SJ733, an oral ATP4 inhibitor of Plasmodium falciparum, with the pharmacokinetic enhancer cobicistat: An innovative approach in antimalarial drug development
por: Gaur, Aditya H., et al.
Publicado: (2022)

New In Vitro Interaction-Parasite Reduction Ratio Assay for Early Derisk in Clinical Development of Antimalarial Combinations
por: Wicha, Sebastian G., et al.
Publicado: (2022)

Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers
por: McCarthy, James S., et al.
Publicado: (2016)

Evaluation of safety and immunogenicity of a group A streptococcus vaccine candidate (MJ8VAX) in a randomized clinical trial
por: Sekuloski, Silvana, et al.
Publicado: (2018)

Safety, Tolerability, and Parasite Clearance Kinetics in Controlled Human Malaria Infection after Direct Venous Inoculation of Plasmodium falciparum Sporozoites: A Model for Evaluating New Blood-Stage Antimalarial Drugs
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum
por: McCarthy, James S., et al.
Publicado: (2021)

Development and application of a PBPK modeling strategy to support antimalarial drug development
por: Abla, Nada, et al.
Publicado: (2023)

Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study
por: McCarthy, James S, et al.
Publicado: (2021)

Haematological response in experimental human Plasmodium falciparum and Plasmodium vivax malaria
por: Woolley, Stephen D., et al.
Publicado: (2021)

Antimalarial drug discovery: progress and approaches
por: Siqueira-Neto, Jair L, et al.
Publicado: (2023)

In vitro and in vivo characterization of the antimalarial lead compound SSJ-183 in Plasmodium models
por: Schleiferböck, Sarah, et al.
Publicado: (2013)

Marine Microbiome as a Source of Antimalarials
por: McCarthy, Peter J., et al.
Publicado: (2019)

The Dynamics of Liver Function Test Abnormalities after Malaria Infection: A Retrospective Observational Study
por: Woodford, John, et al.
Publicado: (2018)

Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia
por: Watts, Rebecca E., et al.
Publicado: (2020)

Safety and Reproducibility of a Clinical Trial System Using Induced Blood Stage Plasmodium vivax Infection and Its Potential as a Model to Evaluate Malaria Transmission
por: Griffin, Paul, et al.
Publicado: (2016)

Characterizing the Blood-Stage Antimalarial Activity of Tafenoquine in Healthy Volunteers Experimentally Infected With Plasmodium falciparum
por: Barber, Bridget E, et al.
Publicado: (2023)

Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia
por: Ménard, Didier, et al.
Publicado: (2019)

265. Rocky Mountain Spotted Fever Encephalopathy
por: Isaac, Sangeetha, et al.
Publicado: (2021)

Successful Removal of 265 Cm. of Gangrenous Intestine
por: Park, Roswell
Publicado: (1903)

SAT-265 Diabetes Distress in Adolescents with Type 1 Diabetes Transitioning to Adult Care
por: Leung, Joseph, et al.
Publicado: (2019)

Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial
por: Phyo, Aung Pyae, et al.
Publicado: (2016)

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Coadministered Ruxolitinib and Artemether-Lumefantrine in Healthy Adults
por: Chughlay, M. Farouk, et al.
Publicado: (2022)

265 Wait at Least 60 Minutes After Eating
por: Gandhi, Stella, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_sm4jtjnemnum82jga99g6hdg85